Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Launches MS Drug Tysabri, Avonex Pen In Japan

This article was originally published in PharmAsia News

Executive Summary

Biogen Idec Japan has launched the humanized monoclonal antibody Tysabri 300 mg (natalizumab) infusion for multiple sclerosis treatment and the interferon beta agent Avonex (interferon beta-1a) Pen on June 4, the company announced on the same day.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC087550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel